Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers 
OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India 
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold 
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
Novo Nordisk (NYSE:NVO) forecasted slower sales growth for 2025, reflecting an expected moderation in demand for its blockbuster obesity drug, Wegovy. The Danish pharmaceutical giant projects local currency sales growth between 16% and 24%, down from 26% in 2024 but aligning with analysts' expectations of around 20%.
Novo Nordisk faces increasing competition from Eli Lilly (NYSE:LLY), a key rival in the weight-loss drug market. Despite this, the company reported strong fourth-quarter results, with operating profit surging 37% to 36.7 billion Danish crowns ($5.12 billion), surpassing analysts' estimates of 33.6 billion. For 2025, the company expects operating profit growth between 19% and 27%, compared to last year's 26%.
Wegovy sales more than doubled in Q4, reaching 19.9 billion crowns, up from 9.6 billion a year earlier and exceeding the 17.3 billion recorded in Q3. The sustained demand underscores the drug’s strong market position, although future growth is expected to decelerate.
As the weight-loss drug market evolves, Novo Nordisk continues to navigate supply constraints and rising competition. Investors remain focused on the company’s long-term outlook as it balances expansion efforts with growing market challenges.
